<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71101">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180165</url>
  </required_header>
  <id_info>
    <org_study_id>5592-101</org_study_id>
    <secondary_id>142639</secondary_id>
    <nct_id>NCT02180165</nct_id>
  </id_info>
  <brief_title>Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)</brief_title>
  <official_title>A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess and compare the safety of posaconazole with
      voriconazole in Japanese participants with Aspergillosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2014</start_date>
  <completion_date type="Anticipated">February 8, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with an Adverse Event</measure>
    <time_frame>Up to approximately Day 98</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants successfully treated for Invasive Aspergillosis</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants successfully treated for Chronic Pulmonary Aspergillosis</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Posaconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voriconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days</description>
    <arm_group_label>Posaconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days</description>
    <arm_group_label>Voriconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight &gt;=45 kg

          -  Can be treated by taking tablet orally or intravenous (IV) formulation via central
             vein

          -  Female has a negative pregnancy test

          -  Female of non-childbearing potential; or if of childbearing potential, agrees to use
             proper combination of barrier method of birth control

          -  Met screening criteria for either Invasive Aspergillosis, Chronic pulmonary
             aspergillosis, Zygomycosis or Fusariosis.

        Exclusion Criteria:

          -  Has a fungal infection other than Aspergillus any species (spp.) Zygomycetes
             (including Mucor spp.) and Fusarium spp. infection

          -  Has allergic bronchopulmonary aspergillosis, allergic sinusitis of aspergillosis, or
             aspergillosis of the eye

          -  Has long-term inactive aspergilloma not expected to respond to investigational
             product

          -  Is not expected to survive study duration

          -  Has an underlying disease, complication and systemic condition which makes it
             difficult to evaluate effect of study drug

          -  Has received, or continues to receive any systemic antifungal therapy, and cannot
             discontinue this treatment; but if fungal infection does not improve, can switch to
             study drug

          -  Is expected to need prohibited medications

          -  Has received posaconazole, has received voriconazole for this infection in the past
             and has deep-seated fungal infection that has not responded to this treatment, has
             intolerance for azole antifungal treatments, or is receiving antifungal combination
             therapy for chronic pulmonary aspergillosis

          -  Has known hypersensitivity to any medication

          -  Has history of either Torsade de Pointes, myocardial infarction within previous 90
             days, has congenital or acquired long QT interval syndrome, or unstable cardiac
             arrhythmia

          -  Has significant liver dysfunction

          -  Has liver cirrhosis or cholestasis

          -  Has renal insufficiency

          -  Has a known hereditary problem of either galactose intolerance, Lapp lactase
             deficiency, or glucose-galactose malabsorption

          -  Has acute symptomatic pancreatitis within 6 months of study entry or chronic
             pancreatitis

          -  Has an active skin lesion consistent with squamous cell carcinoma or melanoma, or
             within prior 5 years a history of malignant melanoma

          -  Has known or suspected Gilbert's disease

          -  Female is pregnant, or nursing, or intends to become pregnant within 14 days after
             end of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>July 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
